Home / Themes / GLP-1 Short '24: Medical Devices & Monitoring
GLP-1 Short '24: Medical Devices & Monitoring
Last updated
Theme thesis · 3/5 sections · Tickers 5 with notes · 5 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsAs of Spring 2025, the thesis for the GLP-1 '24: Medical Devices & Monitoring subtheme is bearish. The advent of GLP-1 drugs has significantly reduced the need
Thesis
As of Spring 2025, the thesis for the GLP-1 '24: Medical Devices & Monitoring subtheme is bearish. The advent of GLP-1 drugs has significantly reduced the need for medical devices and monitoring tools that are traditionally used for managing obesity-related conditions. This shift is expected to negatively impact companies that manufacture or sell devices for diabetes management, sleep apnea, and bariatric surgery.
Bull case
GLP-1 drugs have proven effective in reducing obesity rates, decreasing the need for devices like CPAP machines and insulin pumps.
Companies like ResMed (RMD) and Inspire Medical Systems (INSP) are experiencing declining sales due to reduced demand for sleep apnea devices.
The shift towards pharmaceutical solutions over surgical interventions is diminishing the market for bariatric surgery-related equipment from companies like Teleflex (TFX).
Bear case
Despite the reduction in obesity, the aging population may still drive demand for certain medical devices, providing a cushion for companies like DaVita (DVA) and Fresenius Medical Care (FMS).
Innovations in medical technology and monitoring could present new opportunities for growth in niche markets, potentially offsetting declines.
Some patients may experience side effects from GLP-1 drugs, leading to a continued need for monitoring devices from companies like Tandem Diabetes Care (TNDM) and Insulet (PODD).
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| GLP-1 prescription rates | Monthly | Tracks the adoption rate and market impact | Google_Sheets |
Upcoming Catalysts
| Catalyst | Estimated Timing | Estimated Date Start | Estimated Date End | Why It Matters | Ticker Or Theme Specific | Source Types | Contributing Tickers | Mention Count | Bridge Mention Count | Base Score | Theme Base Score | Source Weight | Specificity Weight | Macro Bridge | Macro Bridge Multiplier | Theme Importance Score | Theme Score | Manual Override | Date Aggregated | Catalyst Source | Catalyst ID | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scaled international launch of the Mobi insulin pump. | second quarter | 2026-04-01 | 2026-06-30 | Expands the market for Mobi globally, potentially driving international sales growth and competitive positioning. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 1.0 | Regulatory/Policy | 1.35 | 101.3153 | 0.0115 | False | 2026-03-16 | Theme aggregation | |||
| Launch of Mobi insulin pump integration with the FreeStyle Libre 3 Plus continuous glucose monitor in the U.S. | second quarter | 2026-04-01 | 2026-06-30 | Enhances Mobi's offering with a highly sought-after sensor integration, potentially driving US sales and competitive advantage. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 1.0 | Regulatory/Policy | 1.35 | 101.3153 | 0.0115 | False | 2026-03-16 | Theme aggregation | |||
| Global launch of Dexcom's 15-day sensor integration on both Tandem's pumps and platforms. | second quarter | 2026-04-01 | 2026-06-30 | Improves user experience and competitive offering across Tandem's product portfolio, potentially driving sales and customer retention. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 1.0 | Regulatory/Policy | 1.35 | 101.3153 | 0.0115 | False | 2026-03-16 | Theme aggregation | |||
| Submission of 510(k) application to the FDA for Mobi Tubeless, Tandem's first patch pump offering. | second quarter | 2026-04-01 | 2026-06-30 | A critical regulatory step towards commercializing a novel product that could significantly expand Tandem's addressable market and competitive position. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 1.0 | Regulatory/Policy | 1.35 | 101.3153 | 0.0115 | False | 2026-03-16 | Theme aggregation | |||
| Deployment of approximately $1.8 billion in net proceeds from divestitures, including a $1.0 billion share repurchase and $800 million debt repayment. | following the closings of the transactions | 2026-03-01 | 2026-12-31 | These actions are expected to significantly reduce share count and interest expense, leading to a 'meaningfully higher adjusted EPS in 2027 and beyond.' | Theme | earnings_transcript | TFX | 2 | 2 | 0.0002 | 0.2012 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 31.2438 | 0.0273 | False | 2026-03-16 | Theme aggregation | |||
| FDA clearance for Control-IQ+ technology with a pregnancy indication. | recently submitted a 510(k) | 2026-03-01 | 2026-12-31 | Expands the indicated use of Control-IQ+, potentially increasing its addressable market and sales by serving a new patient population. | Theme | earnings_transcript | TNDM | 2 | 2 | 0.0001 | 0.2004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 31.1101 | 0.0085 | False | 2026-03-16 | Theme aggregation | |||
| Clarity on the imposition of additional tariffs (10% or 15%) or potential relief from existing tariffs following a recent Supreme Court decision. | now there is certainly some significant uncertainty | 2026-02-27 | 2026-12-31 | Tariffs directly impact gross margin. A favorable resolution could provide upside to current guidance, while additional tariffs could further pressure profitability. | Theme | earnings_transcript | TFX | 1 | 1 | 0.0002 | 0.0012 | 1.25 | 0.92 | Regulatory/Policy, Court/Legal | 1.755 | 0.2519 | 0.0399 | False | 2026-03-16 | Theme aggregation | |||
| Completion of the sale of Teleflex's Acute Care, Interventional Urology, and OEM businesses to two separate buyers. | continue to expect the sales to close in 2026 | 2026-03-01 | 2026-12-31 | This transaction will yield $1.8 billion in net after-tax proceeds, which will be used for significant capital deployment, and will enable the recognition of TS and MS fees to offset stranded costs. | Theme | earnings_transcript | TFX | 1 | 1 | 0.0002 | 0.0012 | 1.25 | 0.92 | Regulatory/Policy, Economic | 1.688 | 0.2422 | 0.0375 | False | 2026-03-16 | Theme aggregation | |||
| Appointment of a new permanent Chief Executive Officer for Teleflex Incorporated. | actively conducting a CEO search | 2026-03-01 | 2026-09-30 | The new CEO will define the long-term strategic direction and operational focus for the 'RemainCo,' impacting investor sentiment and future growth initiatives. | Ticker | earnings_transcript | TFX | 1 | 1 | 0.0001 | 0.001 | 1.25 | 0.92 | 1.0 | 0.1186 | 0.0142 | False | 2026-03-16 | Theme aggregation | ||||
| Full mitigation of $90 million in stranded costs through transition service and manufacturing service agreements, and the completion of a restructuring plan targeting $50 million in annual pre-tax savings. | TS/MS agreements during a transitionary period of time after divestiture close (2026). Restructuring plan substantially completed by mid-2028. | 2026-03-01 | 2028-06-30 | Successful mitigation of these costs is critical for improving adjusted operating margin from the guided 19% in 2026 to an underlying steady-state of approximately 23% and driving significant EPS growth in 2027 and beyond. | Ticker | earnings_transcript | TFX | 1 | 1 | 0.0001 | 0.001 | 1.25 | 0.85 | 1.0 | 0.1096 | 0.0131 | False | 2026-03-16 | Theme aggregation | ||||
| Onboarding and operational ramp of the company's large, national capitated contract (largest in industry) — remaining patient cohorts to be transitioned in H1 2026 after a December Mid-Atlantic go‑live and a February West Coast start. | on schedule in the first half of 2026 (staged starts including a February 1 West Coast start) | 2026-02-01 | 2026-06-30 | This contract is expected to drive 5%–6% of 2026 revenue and requires hiring ~1,200 employees and opening ~30 locations; a timely, high-quality ramp is bullish (accelerates revenue, margin leverage and recurring cash flow), while delays, service failures or cost overruns would materially depress EBITDA, cash flow and investor confidence. | Theme | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0004 | 1.25 | 0.92 | Economic | 1.25 | 0.0526 | 0.0069 | False | 2026-03-16 | Theme aggregation | |||
| CMS competitive bidding program final rule and subsequent contract awards/implementation for the next round of bidding. | upcoming round of competitive bidding (timing uncertain in 2026) | 2026-01-01 | 2026-12-31 | The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth (share gains), while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory (bearish). | Theme | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0004 | 1.25 | 0.92 | 1.0 | 0.0421 | 0.0049 | False | 2026-03-16 | Theme aggregation | ||||
| Full implementation and operationalization of new sales systems in the United States. | in 2026 | 2026-01-01 | 2026-12-31 | Expected to provide significant efficiencies and benefits to the sales team, potentially impacting US sales growth and productivity. | Ticker | earnings_transcript | TNDM | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.92 | 1.0 | 0.0368 | 0.0044 | False | 2026-03-16 | Theme aggregation | ||||
| Quarterly revenue contribution from the capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year‑over‑year growth contribution by Q4 2026. | ramping throughout 2026, peaking at low double‑digits by Q4 2026 | 2026-01-01 | 2026-12-31 | The timing and magnitude of this revenue ramp drive full‑year revenue growth and margin expansion; faster-than-expected ramp is bullish (greater operating leverage), while a slower or smaller ramp is bearish (prolonged margin pressure and higher net leverage). | Ticker | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.92 | 1.0 | 0.0348 | 0.0042 | False | 2026-03-16 | Theme aggregation | ||||
| Rollout of successful AI pilots (order intake AI and conversational AI for PAP self‑scheduling) to additional regions. | in 2026 | 2026-01-01 | 2026-12-31 | Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance, but rollout delays or underperformance would limit anticipated cost savings. | Ticker | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.92 | 1.0 | 0.0348 | 0.0042 | False | 2026-03-16 | Theme aggregation | ||||
| Pursuit and potential closing of tuck‑in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, and associated revolver usage/paydown. | through 2026 | 2026-02-24 | 2026-12-31 | Small acquisitions can smooth transitions and add local capacity (bullish if accretive and enables faster ramp); conversely, additional draws or mis‑timed purchases could elevate leverage or integration risk and pressure near‑term liquidity and margins. | Ticker | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.92 | 1.0 | 0.0348 | 0.0042 | False | 2026-03-16 | Theme aggregation | ||||
| Full implementation and scaling of the pay-as-you-go (PayGo) reimbursement model in the pharmacy channel for both t:slim X2 and Mobi platforms. | beginning late in the first quarter and scaling over the course of 2 to 3 years | 2026-03-01 | 2029-02-20 | This transformational business model change is expected to drive market expansion by reducing upfront costs for customers and improve long-term profitability through higher recurring supply revenue, despite a near-term sales headwind of $70M-$80M in 2026. | Ticker | earnings_transcript | TNDM | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.85 | 1.0 | 0.034 | 0.0041 | False | 2026-03-16 | Theme aggregation | ||||
| Quarterly revenue contribution from AHCO's capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year-over-year growth contribution by Q4 2026. | ramping throughout 2026, peaking at low double-digits by Q4 2026 | 2026-01-01 | 2026-12-31 | The timing and magnitude of this revenue ramp drive full-year revenue growth and margin expansion; faster-than-expected ramp is bullish, while a slower or smaller ramp is bearish. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0037 | False | 2026-02-28 | Theme composer | |||||||
| AHCO plans the rollout of successful AI pilots (order intake AI and conversational AI for PAP self-scheduling) to additional regions. | in 2026 | 2026-01-01 | 2026-12-31 | Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0037 | False | 2026-02-28 | Theme composer | |||||||
| The CMS competitive bidding program's final rule and subsequent contract awards/implementation for the next round of bidding are expected. | upcoming round of competitive bidding (timing uncertain in 2026) | 2026-01-01 | 2026-12-31 | The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth, while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory. | Theme | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0045 | False | 2026-02-28 | Theme composer | |||||||
| AHCO's large, national capitated contract is undergoing onboarding and operational ramp, with remaining patient cohorts transitioning in H1 2026, following a December Mid-Atlantic go-live and a February West Coast start. | on schedule in the first half of 2026 (staged starts including a February 1 West Coast start) | 2026-02-01 | 2026-06-30 | This contract is expected to drive 5%–6% of 2026 revenue and requires significant hiring and new locations; a timely, high-quality ramp is bullish, while delays or cost overruns would materially depress EBITDA, cash flow, and investor confidence. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0037 | False | 2026-02-28 | Theme composer | |||||||
| AHCO is pursuing and potentially closing tuck-in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, with associated revolver usage/paydown. | through 2026 | 2026-02-24 | 2026-12-31 | Small acquisitions can smooth transitions and add local capacity; conversely, additional draws or mis-timed purchases could elevate leverage or integration risk and pressure near-term liquidity and margins. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0037 | False | 2026-02-28 | Theme composer | |||||||
| Onboarding and operational ramp of the company's large, national capitated contract (largest in industry) — remaining patient cohorts to be transitioned in H1 2026 after a December Mid-Atlantic go‑live and a February West Coast start. | on schedule in the first half of 2026 (staged starts including a February 1 West Coast start) | 2026-02-01 | 2026-06-30 | This contract is expected to drive 5%–6% of 2026 revenue and requires hiring ~1,200 employees and opening ~30 locations; a timely, high-quality ramp is bullish (accelerates revenue, margin leverage and recurring cash flow), while delays, service failures or cost overruns would materially depress EBITDA, cash flow and investor confidence. | Ticker | AHCO (ticker) | AHCO_6496a39a | 2026-02-24 | earnings_transcript | ||||||||||||||
| Quarterly revenue contribution from the capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year‑over‑year growth contribution by Q4 2026. | ramping throughout 2026, peaking at low double‑digits by Q4 2026 | 2026-01-01 | 2026-12-31 | The timing and magnitude of this revenue ramp drive full‑year revenue growth and margin expansion; faster-than-expected ramp is bullish (greater operating leverage), while a slower or smaller ramp is bearish (prolonged margin pressure and higher net leverage). | Ticker | AHCO (ticker) | AHCO_8190a9c8 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Rollout of successful AI pilots (order intake AI and conversational AI for PAP self‑scheduling) to additional regions. | in 2026 | 2026-01-01 | 2026-12-31 | Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance, but rollout delays or underperformance would limit anticipated cost savings. | Ticker | AHCO (ticker) | AHCO_5c48eab9 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Pursuit and potential closing of tuck‑in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, and associated revolver usage/paydown. | through 2026 | 2026-02-24 | 2026-12-31 | Small acquisitions can smooth transitions and add local capacity (bullish if accretive and enables faster ramp); conversely, additional draws or mis‑timed purchases could elevate leverage or integration risk and pressure near‑term liquidity and margins. | Ticker | AHCO (ticker) | AHCO_e7c66252 | 2026-02-24 | earnings_transcript | ||||||||||||||
| CMS competitive bidding program final rule and subsequent contract awards/implementation for the next round of bidding. | upcoming round of competitive bidding (timing uncertain in 2026) | 2026-01-01 | 2026-12-31 | The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth (share gains), while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory (bearish). | Theme | AHCO (ticker) | AHCO_2dab6ea0 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Large-scale rollout of the 5008X CAREsystem and high-volume hemodiafiltration (HV-HDF) therapy in U.S. clinics, targeting 20% of the installed base in 2026. | in 2026, target of replacing around 20% of the installed base in our own clinics this year | 2026-01-01 | 2026-12-31 | This strategic initiative is expected to improve patient outcomes, increase operational efficiencies, and strengthen FMS's competitive position, but will incur OpEx headwinds in 2026. Successful execution is crucial for future growth and market share. | Ticker | FMS (ticker) | FMS_a8b53d93 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Continued negative impact from volume-based procurement and other regulatory policies in China on the Care Enablement segment. | expected to impact 2026, China remains challenging, and we are assuming moderately negative impact as we address regulatory policy changes and review our portfolio and strategy accordingly | 2026-01-01 | 2026-12-31 | These policies weighed on revenue and earnings in Q4 2025 and are expected to continue to negatively impact the segment's performance in 2026, with the magnitude dependent on FMS's strategic adjustments. | Ticker | FMS (ticker) | FMS_ed8c2ef3 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Expiry of extended tax subsidies for Affordable Care Act (ACA) contracts. | 2026 outlook, regulatory headwinds from the expiry of the extended tax subsidies for ACA contracts | 2026-01-01 | 2026-12-31 | This regulatory headwind is expected to negatively impact earnings development, contributing to the EUR 150M-EUR 200M regulatory impact in 2026, with the full extent of the financial impact still being assessed. | Ticker | FMS (ticker) | FMS_9d8ae73c | 2026-02-24 | earnings_transcript | ||||||||||||||
| Recovery of U.S. same-market treatment growth (SMTG) from flat in 2026 towards the historical 2%+ baseline. | returning to 2%-plus as mortality normalizes and patient outflows improve, gradually improve over time to get back to that 2% plus | 2026-01-01 | 2028-12-31 | SMTG is a critical driver of revenue and operating leverage. A sustained recovery would signal normalization of patient mortality and successful strategic initiatives, positively impacting long-term growth and valuation. | Ticker | FMS (ticker) | FMS_5e50f090 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Realization of an additional EUR 400 million in sustainable savings from the accelerated FME25+ transformation program by the end of 2027, with EUR 250 million incremental savings expected in 2026. | for the years '26 and 2027 for a total of EUR 1.2 billion of sustainable savings by the end of 2027, incremental FME25+ savings of EUR 250 million with related onetime cost of EUR 350 million in 2026 | 2026-01-01 | 2027-12-31 | This program is a key driver of profitability improvements, aiming for EUR 1.2 billion in total sustainable savings by 2027. Successful execution will significantly boost margins and earnings, offsetting inflationary pressures. | Ticker | FMS (ticker) | FMS_23d3f509 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Launch of Omnipod 5 integration with FreeStyle Libre 3 Plus continuous glucose monitor (CGM). | in the first half of 2026 | 2026-03-01 | 2026-06-30 | This expands Omnipod's compatibility to a major sensor, making it accessible to a broader patient base and potentially increasing market share, impacting demand trajectory and competitive position. | Ticker | PODD (ticker) | PODD_3f4381e7 | 2026-02-18 | earnings_transcript | ||||||||||||||
| Global rollout of Omnipod Discover, a new data platform providing streamlined insights for healthcare professionals and users. | In 2026, we will continue to purposely increase R&D investment to advance our next-generation platforms, including Omnipod 6 as well as our fully closed-loop system for type 2 diabetes and future innovations. This also includes continued progress across our clinical programs with ongoing work in STRIVE and EVOLUTION. | 2026-01-01 | 2026-12-31 | This platform aims to support efficient HCP review, simplify onboarding, and strengthen engagement, potentially improving customer retention and reducing cost to serve, which impacts margins and investor sentiment. | Ticker | PODD (ticker) | PODD_1dde0925 | 2026-02-18 | earnings_transcript | ||||||||||||||
| Presentation of pivotal results from the STRIVE study for Omnipod 6 at the American Diabetes Association (ADA) conference. | pivotal data to be presented at ADA in June | 2026-06-01 | 2026-06-30 | Positive pivotal data is crucial for supporting the regulatory filing and future commercial success of Omnipod 6, demonstrating its advanced features and potential to enhance clinical outcomes and user experience. | Ticker | PODD (ticker) | PODD_87e6177c | 2026-02-18 | earnings_transcript | ||||||||||||||
| Initiation of the pivotal EVOLUTION study for Insulet's fully closed-loop system designed for people with Type 2 diabetes. | We expect to initiate our pivotal EVOLUTION study this year, supporting a regulatory filing in 2027 and a commercial launch in 2028. | 2026-01-01 | 2026-12-31 | This study is a critical step towards regulatory approval and commercialization of a system intended to address a significant unmet need in the large Type 2 diabetes market, potentially transforming Insulet's growth trajectory. | Ticker | PODD (ticker) | PODD_40f7ce65 | 2026-02-18 | earnings_transcript | ||||||||||||||
| Appointment of a new permanent Chief Executive Officer for Teleflex Incorporated. | actively conducting a CEO search | 2026-03-01 | 2026-09-30 | The new CEO will define the long-term strategic direction and operational focus for the 'RemainCo,' impacting investor sentiment and future growth initiatives. | Ticker | TFX (ticker) | TFX_aeb372f2 | 2026-02-26 | earnings_transcript | ||||||||||||||
| Completion of the sale of Teleflex's Acute Care, Interventional Urology, and OEM businesses to two separate buyers. | continue to expect the sales to close in 2026 | 2026-03-01 | 2026-12-31 | This transaction will yield $1.8 billion in net after-tax proceeds, which will be used for significant capital deployment, and will enable the recognition of TS and MS fees to offset stranded costs. | Ticker | TFX (ticker) | TFX_2b3d486d | 2026-02-26 | earnings_transcript | ||||||||||||||
| Deployment of approximately $1.8 billion in net proceeds from divestitures, including a $1.0 billion share repurchase and $800 million debt repayment. | following the closings of the transactions | 2026-03-01 | 2026-12-31 | These actions are expected to significantly reduce share count and interest expense, leading to a 'meaningfully higher adjusted EPS in 2027 and beyond.' | Ticker | TFX (ticker) | TFX_1b402ad4 | 2026-02-26 | earnings_transcript | ||||||||||||||
| Full mitigation of $90 million in stranded costs through transition service and manufacturing service agreements, and the completion of a restructuring plan targeting $50 million in annual pre-tax savings. | TS/MS agreements during a transitionary period of time after divestiture close (2026). Restructuring plan substantially completed by mid-2028. | 2026-03-01 | 2028-06-30 | Successful mitigation of these costs is critical for improving adjusted operating margin from the guided 19% in 2026 to an underlying steady-state of approximately 23% and driving significant EPS growth in 2027 and beyond. | Ticker | TFX (ticker) | TFX_4b85ed60 | 2026-02-26 | earnings_transcript | ||||||||||||||
| Clarity on the imposition of additional tariffs (10% or 15%) or potential relief from existing tariffs following a recent Supreme Court decision. | now there is certainly some significant uncertainty | 2026-02-27 | 2026-12-31 | Tariffs directly impact gross margin. A favorable resolution could provide upside to current guidance, while additional tariffs could further pressure profitability. | Theme | TFX (ticker) | TFX_d6b9173b | 2026-02-26 | earnings_transcript | ||||||||||||||
| Full implementation and operationalization of new sales systems in the United States. | in 2026 | 2026-01-01 | 2026-12-31 | Expected to provide significant efficiencies and benefits to the sales team, potentially impacting US sales growth and productivity. | Ticker | TNDM (ticker) | TNDM_f826e8b2 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Scaled international launch of the Mobi insulin pump. | second quarter | 2026-04-01 | 2026-06-30 | Expands the market for Mobi globally, potentially driving international sales growth and competitive positioning. | Ticker | TNDM (ticker) | TNDM_f62815e7 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Launch of Mobi insulin pump integration with the FreeStyle Libre 3 Plus continuous glucose monitor in the U.S. | second quarter | 2026-04-01 | 2026-06-30 | Enhances Mobi's offering with a highly sought-after sensor integration, potentially driving US sales and competitive advantage. | Ticker | TNDM (ticker) | TNDM_25623f39 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Global launch of Dexcom's 15-day sensor integration on both Tandem's pumps and platforms. | second quarter | 2026-04-01 | 2026-06-30 | Improves user experience and competitive offering across Tandem's product portfolio, potentially driving sales and customer retention. | Ticker | TNDM (ticker) | TNDM_ec4ae537 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Submission of 510(k) application to the FDA for Mobi Tubeless, Tandem's first patch pump offering. | second quarter | 2026-04-01 | 2026-06-30 | A critical regulatory step towards commercializing a novel product that could significantly expand Tandem's addressable market and competitive position. | Ticker | TNDM (ticker) | TNDM_99373d95 | 2026-02-20 | earnings_transcript | ||||||||||||||
| FDA clearance for Control-IQ+ technology with a pregnancy indication. | recently submitted a 510(k) | 2026-03-01 | 2026-12-31 | Expands the indicated use of Control-IQ+, potentially increasing its addressable market and sales by serving a new patient population. | Ticker | TNDM (ticker) | TNDM_e141eabd | 2026-02-20 | earnings_transcript | ||||||||||||||
| Full implementation and scaling of the pay-as-you-go (PayGo) reimbursement model in the pharmacy channel for both t:slim X2 and Mobi platforms. | beginning late in the first quarter and scaling over the course of 2 to 3 years | 2026-03-01 | 2029-02-20 | This transformational business model change is expected to drive market expansion by reducing upfront costs for customers and improve long-term profitability through higher recurring supply revenue, despite a near-term sales headwind of $70M-$80M in 2026. | Ticker | TNDM (ticker) | TNDM_66b9a22c | 2026-02-20 | earnings_transcript | ||||||||||||||
| FDA clearance for Mobi Tubeless, enabling its commercial launch. | second half of the year | 2026-07-01 | 2026-12-31 | Regulatory approval is necessary to launch this significant new product, which is Tandem's first patch pump and the world's first with extended wear technology, potentially impacting market share and revenue. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 93.2101 | 0.0106 | False | 2026-03-16 | Theme aggregation | |||
| Commercial launch of Mobi Tubeless, a novel infusion site option for the Mobi pump that transforms it into a tubeless patch device. | second half of the year | 2026-07-01 | 2026-12-31 | Introduces a new form factor and technology, potentially expanding Tandem's addressable market and competitive position against patch pump competitors, though not included in 2026 revenue guidance. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 93.2101 | 0.0106 | False | 2026-03-16 | Theme aggregation | |||
| Initiation of a pivotal trial for Tandem's fully closed-loop automated insulin delivery algorithm. | later this year | 2026-07-01 | 2026-12-31 | A crucial step towards developing a next-generation AID system, aiming for FDA filing in 2027, which is vital for maintaining Tandem's leadership in AID innovation. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 93.2101 | 0.0106 | False | 2026-03-16 | Theme aggregation | |||
| Effectiveness of diabetes segment recovery initiatives (expanded diabetes sales force and pharmacy/channel investments) to drive a rebound in CGM new starts and continued pump growth. | later in 2026 | 2026-07-01 | 2026-12-31 | Diabetes performance is a key swing factor for organic growth and valuation; a tangible rebound in new starts would be bullish (restores a previously weak segment and supports guidance), while persistent softness would reinforce downside risk from secular pressures (including GLP‑1 adoption) and hurt revenue and margin outlooks. | Theme | earnings_transcript | AHCO | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 93.2068 | 0.01 | False | 2026-03-16 | Theme aggregation | |||
| Effectiveness of diabetes segment recovery initiatives (expanded diabetes sales force and pharmacy/channel investments) to drive a rebound in CGM new starts and continued pump growth. | later in 2026 | 2026-07-01 | 2026-12-31 | Diabetes performance is a key swing factor for organic growth and valuation; a tangible rebound in new starts would be bullish (restores a previously weak segment and supports guidance), while persistent softness would reinforce downside risk from secular pressures (including GLP‑1 adoption) and hurt revenue and margin outlooks. | Ticker | AHCO (ticker) | AHCO_00fc6f4a | 2026-02-24 | earnings_transcript | ||||||||||||||
| Phasing out of temporary TDAPA (Transitional Drug Add-on Payment Adjustment) benefits for phosphate binders and antimicrobial catheter solutions. | start to phase out in 2026, stronger first half of 2026 before TDAPA benefits begin to phase out in the second half of 2026 | 2026-07-01 | 2026-12-31 | These benefits provided a significant positive contribution to earnings in 2025. Their phase-out will create a regulatory headwind of EUR 150M-EUR 200M in 2026, impacting profitability, with uncertainty around the exact erosion of branded pricing and future bundle payments. | Ticker | FMS (ticker) | FMS_b10690dc | 2026-02-24 | earnings_transcript | ||||||||||||||
| Commercial launch of Omnipod 5 in Spain, a new international market. | Spain, our newest market, is expected to launch Omnipod 5 later this year. | 2026-07-01 | 2026-12-31 | Entry into new geographies is a key component of Insulet's international growth strategy, driving volume and market share gains, which directly impacts revenue and investor sentiment. | Ticker | PODD (ticker) | PODD_4c284f22 | 2026-02-18 | earnings_transcript | ||||||||||||||
| FDA clearance for Mobi Tubeless, enabling its commercial launch. | second half of the year | 2026-07-01 | 2026-12-31 | Regulatory approval is necessary to launch this significant new product, which is Tandem's first patch pump and the world's first with extended wear technology, potentially impacting market share and revenue. | Ticker | TNDM (ticker) | TNDM_82e30c2b | 2026-02-20 | earnings_transcript | ||||||||||||||
| Commercial launch of Mobi Tubeless, a novel infusion site option for the Mobi pump that transforms it into a tubeless patch device. | second half of the year | 2026-07-01 | 2026-12-31 | Introduces a new form factor and technology, potentially expanding Tandem's addressable market and competitive position against patch pump competitors, though not included in 2026 revenue guidance. | Ticker | TNDM (ticker) | TNDM_a7005c10 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Initiation of a pivotal trial for Tandem's fully closed-loop automated insulin delivery algorithm. | later this year | 2026-07-01 | 2026-12-31 | A crucial step towards developing a next-generation AID system, aiming for FDA filing in 2027, which is vital for maintaining Tandem's leadership in AID innovation. | Ticker | TNDM (ticker) | TNDM_8eea9c45 | 2026-02-20 | earnings_transcript | ||||||||||||||
| CMS decision on the National Coverage Determination (NCD) for C-peptide testing, following a request from the Senate. | August of '26 | 2026-08-01 | 2026-08-31 | A favorable decision would substantially improve Medicare access for people with Type 2 diabetes, expanding Tandem's addressable market and potentially driving new pump starts in this segment. | Theme | earnings_transcript | TNDM | 1 | 1 | 0.0 | 0.0004 | 1.25 | 1.05 | 1.0 | 0.0508 | 0.006 | False | 2026-03-16 | Theme aggregation | ||||
| CMS decision on the National Coverage Determination (NCD) for C-peptide testing, following a request from the Senate. | August of '26 | 2026-08-01 | 2026-08-31 | A favorable decision would substantially improve Medicare access for people with Type 2 diabetes, expanding Tandem's addressable market and potentially driving new pump starts in this segment. | Theme | TNDM (ticker) | TNDM_6065a6be | 2026-02-20 | earnings_transcript | ||||||||||||||
| Transition to direct commercial operations in additional key European markets, following the playbook from initial transitions. | in the fourth quarter | 2026-10-01 | 2026-12-31 | Expected to improve price and margins (ASP premiums at least 30% higher) and deepen relationships, but also involves an anticipated $15 million headwind from distributor destocking and inventory buybacks for 2026. | Ticker | earnings_transcript | TNDM | 1 | 1 | 0.0 | 0.0003 | 1.25 | 1.0 | 1.0 | 0.04 | 0.0048 | False | 2026-03-16 | Theme aggregation | ||||
| Transition to direct commercial operations in additional key European markets, following the playbook from initial transitions. | in the fourth quarter | 2026-10-01 | 2026-12-31 | Expected to improve price and margins (ASP premiums at least 30% higher) and deepen relationships, but also involves an anticipated $15 million headwind from distributor destocking and inventory buybacks for 2026. | Ticker | TNDM (ticker) | TNDM_709c0ea7 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Regulatory filing for Insulet's fully closed-loop system for Type 2 diabetes. | supporting a regulatory filing in 2027 | 2027-01-01 | 2027-12-31 | Successful regulatory filing is a prerequisite for commercial launch, enabling Insulet to access the vast and underpenetrated Type 2 diabetes market with a highly differentiated product, impacting future revenue and valuation. | Ticker | PODD (ticker) | PODD_5dda514d | 2026-02-18 | earnings_transcript | ||||||||||||||
| Commercial launch of Insulet's next-generation Omnipod 6 system. | accelerate our innovation cycle as we prepare for launch in 2027 | 2027-01-01 | 2027-12-31 | This next-gen platform is designed to offer improved connectivity, flexibility, and personalized automation, crucial for maintaining competitive leadership and driving future revenue growth and investor sentiment. | Ticker | PODD (ticker) | PODD_93a0b76a | 2026-02-18 | earnings_transcript | ||||||||||||||
| Commercial launch of Insulet's fully closed-loop system for people with Type 2 diabetes. | a commercial launch in 2028 | 2028-01-01 | 2028-12-31 | This system is designed to make AID accessible to virtually everyone with Type 2 diabetes, significantly expanding the addressable market and driving future growth, potentially solidifying Insulet's leadership in this segment. | Ticker | PODD (ticker) | PODD_fdc63d7d | 2026-02-18 | earnings_transcript | ||||||||||||||
| Insulet's new manufacturing facility in Costa Rica becomes operational. | expected to be operational in 2029 | 2029-01-01 | 2029-12-31 | This investment in capacity and automation is critical for supporting long-term industry-leading growth and achieving continued margin expansion, impacting profitability and valuation. | Ticker | PODD (ticker) | PODD_55d4bc0d | 2026-02-18 | earnings_transcript |